Trimethoprim - Generic Drug Details

What are the generic drug sources for trimethoprim and what is the scope of freedom to operate?

Trimethoprim is the generic ingredient in five branded drugs marketed by Monarch Pharms, Dr Reddys Labs Sa, Novel Labs Inc, Novitium Pharma, Sun Pharm Industries, Teva, Watson Labs, Roche, and Pangea, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are thirty-four drug master file entries for trimethoprim. Five suppliers are listed for this compound.

Summary for trimethoprim

US Patents:	0
Tradenames:	5
Applicants:	9
NDAs:	11
Drug Master File Entries:	34
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	138
Clinical Trials:	203
Patent Applications:	7,680
Drug Prices:	Drug price trends for trimethoprim
What excipients (inactive ingredients) are in trimethoprim?	trimethoprim excipients list
DailyMed Link:	trimethoprim at DailyMed

See drug prices for trimethoprim

See drug sales revenues for trimethoprim

Recent Clinical Trials for trimethoprim

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	PHASE4
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE4
University of Pennsylvania	PHASE1

See all trimethoprim clinical trials

Pharmacology for trimethoprim

Drug Class	Dihydrofolate Reductase Inhibitor Antibacterial
Mechanism of Action	Cytochrome P450 2C8 Inhibitors Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors

Medical Subject Heading (MeSH) Categories for trimethoprim

Anti-Infective Agents, Urinary

Antimalarials

Cytochrome P-450 CYP2C8 Inhibitors

Folic Acid Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for trimethoprim

J01EA	Trimethoprim and derivatives
J01E	SULFONAMIDES AND TRIMETHOPRIM
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for trimethoprim

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva	TRIMETHOPRIM	trimethoprim	TABLET;ORAL	071259-001	Jun 18, 1987		DISCN	No	No
Monarch Pharms	PROLOPRIM	trimethoprim	TABLET;ORAL	017943-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pangea	PRIMSOL	trimethoprim hydrochloride	SOLUTION;ORAL	074973-001	Jan 24, 2000		DISCN	Yes	No

Trimethoprim Market Analysis and Financial Projection

Last updated: February 12, 2026

How Does the Market for Trimethoprim Evolve?

Trimethoprim is an established antibiotic primarily used for urinary tract infections (UTIs). The market landscape is shifting due to evolving resistance patterns, regulatory policies, and clinical guidelines.

Market Size and Growth

The global antimicrobial agents market was valued at approximately $56 billion in 2022, with antibiotics representing around 40% of this figure. Trimethoprim, as part of the combination drug trimethoprim-sulfamethoxazole (TMP-SMX), accounts for a significant share within urinary tract infection treatments.

In the United States, higher prescription volumes are driven by UTIs accounting for roughly 8 million office visits annually. The European market registers similar demand, while Asian markets show rapid growth due to increasing healthcare infrastructure and antibiotic consumption.

Between 2020 and 2025, the compound annual growth rate (CAGR) for antibiotics targeting UTIs is projected at roughly 2.5%, with trimethoprim's contribution stabilizing due to resistance issues.

Drivers and Challenges

Drivers:

• High efficacy against common pathogens like Escherichia coli.
• Low cost and widespread availability.
• Established clinical protocols for uncomplicated UTIs.

Challenges:

• Rising resistance reduces clinical utility.
• Regulatory restrictions in some markets due to resistance concerns.
• Emergence of alternative antibiotics with broader spectra.

Resistance Trends and Impact

Antibiotic resistance has been a key concern for trimethoprim. Data indicates increasing resistance rates, notably in E. coli strains, with reports of resistance exceeding 20% in some regions. The CDC reports a similar trend globally, prompting revisions of prescribing guidelines.

Resistant strains lead to higher treatment failures, increasing healthcare costs and prompting a shift toward second-line agents, which tend to be more expensive and have broader side effect profiles.

Regulatory Environment and Patent Status

Trimethoprim itself is off-patent. The drug is available as a generic in most regions, reducing incentives for R&D investment. Regulatory agencies, such as the FDA, have issued updated guidelines emphasizing antimicrobial stewardship, which may influence prescribing patterns and market dynamics.

New formulations or combination therapies with improved resistance profiles might attract regulatory approval, but there is limited pipeline activity for novel formulations specifically targeting trimethoprim's resistance issues.

---

What Are the Financial Trajectories for Trimethoprim?

Revenue Trends

The decline in patent protection means revenues are primarily driven by generic sales. Estimated global sales of trimethoprim and its combinations are approximately $200 million annually, with the U.S. accounting for over 50%.

Market revenues are expected to decrease marginally over the next five years due to resistance and the rise of alternative therapies, unless new formulations or indications are developed.

Cost and Pricing Dynamics

Generic manufacturers dominate the market, leading to low prices. The average wholesale price (AWP) for a course of trimethoprim ranges from $1 to $5 in the U.S., depending on dosage and formulation. Price competition constrains profit margins but supports volume sales.

Cost Structure:

• Manufacturing costs are low, estimated at under $0.50 per course.
• Marketing expenditure is minimal, primarily for stewardship campaigns.

R&D and Innovation Investment

Limited R&D investment occurs at this stage, given the drug's off-patent status. Firms focus on formulating combination drugs or expanding indications rather than developing new chemical entities.

Some biotech companies are exploring hybrid molecules or adjunct therapies to overcome resistance, but these are at early development stages. The financial risk for innovation is high, with probable delays in regulatory approval.

Future Investment and Market Opportunities

Opportunities lie in developing combinations with newer antibiotics or formulations targeting resistant strains. Investment in diagnostics to identify susceptible infections could revive trimethoprim's use, presenting a niche market.

However, such innovations require significant capital outlay with uncertain market returns, given the current resistance landscape and competition from broader-spectrum antibiotics.

---

Key Takeaways

• The global antibiotics market, valued at approximately $56 billion in 2022, supports trimethoprim's steady but mature role.
• Rising resistance rates diminish trimethoprim's clinical efficacy, leading to slower market growth and potential revenue decline.
• The drug's patent expiry and generic status keep prices low and margins minimal.
• Limited R&D activity exists, but opportunities for combination therapies and diagnostics may extend the drug's relevance.
• Market revenues are forecasted to decline modestly unless new formulations or indications are developed.

---

FAQs

1. How does resistance affect trimethoprim's market?
Resistance reduces clinical efficacy, prompting guideline revisions and shifting prescribing to alternative antibiotics, leading to market contraction.

2. Are there any new formulations of trimethoprim in development?
Limited activity exists; most efforts focus on combination drugs or diagnostics rather than new formulations due to the off-patent status.

3. What is the outlook for generic manufacturers?
They will maintain sales volume with low margins. The market is mature, with minimal growth prospects unless targeted innovations emerge.

4. Could antimicrobial stewardship policies impact trimethoprim?
Yes, stricter stewardship could limit use, especially if resistance continues to rise, further decreasing demand.

5. Is there potential in developing resistance-overcoming therapies?
Yes, innovative combination therapies targeting resistant strains could create niche markets but require significant R&D investment.

---

References

1. IQVIA, “Global Veterinary and Human Antibiotics Market Report,” 2022.
2. CDC, “Antibiotic Resistance Threats in the United States,” 2019.
3. EvaluatePharma, “Pipeline Tracking 2023,” 2023.
4. FDA, “Guidelines for Antimicrobial Stewardship,” 2021.
5. Statista, “Global Market Size for Antibiotics,” 2022.